SCOTTSDALE, Ariz., Jan. 4, 2010 -- Medicis (NYSE:MRX) today announced that the Company is scheduled to present at the Goldman Sachs Healthcare CEOs Unscripted Conference in New York City. A live webcast of its presentation scheduled for Wednesday, January 6, 2010, at 1:15 p.m. Eastern Time (10:15 a.m. Pacific Time), may be accessed via the Internet.
The webcast will be available via a link on the Medicis corporate website at http://www.Medicis.com/company/index.asp. This link will allow visitors to the website to access the Medicis presentation. An archive of the webcast will be available on the Medicis corporate website for 10 business days following the live presentation.
Medicis is the leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of dermatological and aesthetic conditions. The Company is dedicated to helping patients attain a healthy and youthful appearance and self-image. Medicis has leading branded prescription products in a number of therapeutic and aesthetic categories. The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.
The Company's products include the brands DYSPORT(TM) (abobotulinumtoxinA) 300 Units for Injection, PERLANE(R), RESTYLANE(R), DYNACIN(R) (minocycline HCl Tablets, USP), LIDEX(R) (fluocinonide) Cream 0.05%, LOPROX(R) (ciclopirox) Gel 0.77% and Shampoo 1%, PLEXION(R) (sodium sulfacetamide 10% and sulfur 5%) Cleanser, Cleansing Cloths, Cream and Topical Suspension, SOLODYN(R) (minocycline HCl, USP) Extended Release Tablets, TRIAZ(R) (benzoyl peroxide) 3%, 6% and 9% Cleansers, Gels and Pads, and 3% and 6% Foaming Cloths, VANOS(R) (fluocinonide) Cream 0.1%, ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10%, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder, the LIPOSONIX(TM)(1) system and the over-the-counter brand ESOTERICA(R).
For more information about Medicis, please visit the Company's website at www.Medicis.com. Printed copies of the Company's complete audited financial statements are available free of charge upon request.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. All statements included in this press release that address activities, events or developments that Medicis expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by Medicis based on its experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. No assurances can be given, however, that these activities, events or developments will occur or that such results will be achieved. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of Medicis. Several of these risks are outlined in the Company's most recent annual report on Form 10-K for the year ended December 31, 2008, and other documents we file with the Securities and Exchange Commission. Forward-looking statements represent the judgment of Medicis management as of the date of this release, and Medicis disclaims any intent or obligation to update any forward-looking statements contained herein, which speak as of the date hereof.
NOTE: Full prescribing information for any Medicis prescription product is available by contacting the Company. All trademarks are the property of their respective owners.
(1) The LIPOSONIX(TM) system is not approved or cleared for sale in the U.S.
CONTACT: Medicis Kara Stancell (480) 291-5854